 Felicia Allard
Concepts (154)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intestinal Mucosa | 3 | 2020 | 224 | 1.260 |
Why?
| | Competency-Based Education | 1 | 2024 | 29 | 0.910 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 127 | 0.830 |
Why?
| | Clinical Competence | 1 | 2024 | 406 | 0.730 |
Why?
| | Nonprescription Drugs | 1 | 2019 | 34 | 0.620 |
Why?
| | Gastric Mucosa | 1 | 2019 | 45 | 0.610 |
Why?
| | Prescription Drugs | 1 | 2019 | 41 | 0.610 |
Why?
| | Ampulla of Vater | 1 | 2018 | 17 | 0.590 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2018 | 20 | 0.590 |
Why?
| | Cytodiagnosis | 1 | 2018 | 43 | 0.580 |
Why?
| | Dacryocystitis | 2 | 2015 | 4 | 0.550 |
Why?
| | Pancreatic Neoplasms | 3 | 2024 | 216 | 0.490 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2018 | 332 | 0.470 |
Why?
| | Keratin-17 | 2 | 2024 | 2 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2018 | 649 | 0.430 |
Why?
| | Crohn Disease | 3 | 2021 | 117 | 0.430 |
Why?
| | Nasolacrimal Duct | 1 | 2013 | 10 | 0.420 |
Why?
| | Anesthetics, Local | 1 | 2013 | 79 | 0.400 |
Why?
| | Biopsy, Fine-Needle | 3 | 2024 | 107 | 0.390 |
Why?
| | Cocaine | 1 | 2013 | 177 | 0.380 |
Why?
| | Cocaine-Related Disorders | 1 | 2013 | 207 | 0.360 |
Why?
| | Gastrointestinal Agents | 2 | 2021 | 41 | 0.340 |
Why?
| | Biopsy | 4 | 2020 | 605 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 236 | 0.310 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2024 | 40 | 0.270 |
Why?
| | Humans | 21 | 2024 | 52483 | 0.230 |
Why?
| | Dacryocystorhinostomy | 2 | 2015 | 10 | 0.230 |
Why?
| | Pathology | 1 | 2024 | 38 | 0.220 |
Why?
| | Suture Techniques | 2 | 2014 | 60 | 0.220 |
Why?
| | Alanine Transaminase | 2 | 2023 | 122 | 0.210 |
Why?
| | Liver Diseases | 1 | 2023 | 83 | 0.200 |
Why?
| | Immunohistochemistry | 3 | 2024 | 979 | 0.200 |
Why?
| | Education, Medical, Graduate | 1 | 2024 | 219 | 0.190 |
Why?
| | Retrospective Studies | 7 | 2021 | 6607 | 0.190 |
Why?
| | Aged, 80 and over | 6 | 2024 | 3392 | 0.190 |
Why?
| | Strongyloides stercoralis | 1 | 2022 | 6 | 0.190 |
Why?
| | Strongyloidiasis | 1 | 2022 | 10 | 0.190 |
Why?
| | Colitis | 1 | 2022 | 51 | 0.180 |
Why?
| | Biological Factors | 1 | 2021 | 12 | 0.180 |
Why?
| | Endoscopy, Gastrointestinal | 2 | 2018 | 76 | 0.170 |
Why?
| | Duodenal Neoplasms | 1 | 2020 | 15 | 0.170 |
Why?
| | Methamphetamine | 1 | 2022 | 198 | 0.160 |
Why?
| | Immunity, Innate | 1 | 2020 | 117 | 0.160 |
Why?
| | Male | 12 | 2024 | 26761 | 0.160 |
Why?
| | Spinal Diseases | 1 | 2019 | 15 | 0.160 |
Why?
| | Aged | 8 | 2024 | 10121 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 944 | 0.160 |
Why?
| | Blastomycosis | 1 | 2019 | 31 | 0.160 |
Why?
| | Middle Aged | 9 | 2024 | 13028 | 0.150 |
Why?
| | Claudin-1 | 1 | 2018 | 4 | 0.150 |
Why?
| | Magnetic Resonance Imaging | 2 | 2015 | 1546 | 0.150 |
Why?
| | Zonula Occludens-1 Protein | 1 | 2018 | 7 | 0.150 |
Why?
| | Lumbar Vertebrae | 1 | 2019 | 104 | 0.150 |
Why?
| | Adult | 7 | 2024 | 14161 | 0.150 |
Why?
| | Observer Variation | 1 | 2018 | 134 | 0.150 |
Why?
| | Cation Transport Proteins | 1 | 2018 | 27 | 0.140 |
Why?
| | Oculomotor Muscles | 2 | 2014 | 22 | 0.140 |
Why?
| | Sutures | 2 | 2014 | 39 | 0.140 |
Why?
| | Eyelids | 2 | 2014 | 29 | 0.140 |
Why?
| | Prognosis | 2 | 2024 | 2099 | 0.140 |
Why?
| | Cell Proliferation | 2 | 2018 | 1023 | 0.140 |
Why?
| | Neoplasm Metastasis | 1 | 2018 | 243 | 0.140 |
Why?
| | Colonic Pouches | 1 | 2015 | 7 | 0.120 |
Why?
| | Adenomatous Polyposis Coli | 1 | 2015 | 6 | 0.120 |
Why?
| | Pancreatic Cyst | 1 | 2015 | 10 | 0.120 |
Why?
| | Rectal Neoplasms | 1 | 2015 | 53 | 0.120 |
Why?
| | Endosonography | 1 | 2015 | 98 | 0.120 |
Why?
| | Colitis, Ulcerative | 1 | 2015 | 67 | 0.120 |
Why?
| | Ectropion | 1 | 2014 | 2 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2018 | 1229 | 0.110 |
Why?
| | Enchondromatosis | 1 | 2014 | 1 | 0.110 |
Why?
| | Ophthalmologic Surgical Procedures | 1 | 2014 | 21 | 0.110 |
Why?
| | Entropion | 1 | 2014 | 1 | 0.110 |
Why?
| | Female | 10 | 2024 | 28171 | 0.110 |
Why?
| | Chondrosarcoma | 1 | 2014 | 12 | 0.110 |
Why?
| | Blepharoptosis | 1 | 2014 | 13 | 0.110 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 1 | 2014 | 46 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 857 | 0.110 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2013 | 7 | 0.110 |
Why?
| | Azithromycin | 1 | 2013 | 26 | 0.110 |
Why?
| | Administration, Intranasal | 1 | 2013 | 31 | 0.110 |
Why?
| | Fluoroquinolones | 1 | 2013 | 25 | 0.110 |
Why?
| | Bronchoscopy | 1 | 2014 | 76 | 0.110 |
Why?
| | Follow-Up Studies | 1 | 2018 | 2279 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 639 | 0.090 |
Why?
| | Treatment Outcome | 5 | 2021 | 5422 | 0.090 |
Why?
| | Rats, Wistar | 2 | 2022 | 193 | 0.090 |
Why?
| | Animals | 5 | 2023 | 13505 | 0.080 |
Why?
| | Acetaminophen | 2 | 2023 | 279 | 0.080 |
Why?
| | Diagnosis, Differential | 3 | 2019 | 1046 | 0.080 |
Why?
| | Postoperative Complications | 1 | 2015 | 1068 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 1165 | 0.070 |
Why?
| | Lung Neoplasms | 1 | 2014 | 636 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 807 | 0.070 |
Why?
| | Mice | 3 | 2023 | 5949 | 0.060 |
Why?
| | Liver | 2 | 2022 | 1156 | 0.060 |
Why?
| | Rats | 2 | 2022 | 3220 | 0.060 |
Why?
| | Deoxycytidine | 1 | 2024 | 29 | 0.060 |
Why?
| | Fluorouracil | 1 | 2024 | 59 | 0.060 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2024 | 39 | 0.060 |
Why?
| | Contrast Media | 2 | 2015 | 193 | 0.060 |
Why?
| | Pyruvic Acid | 1 | 2023 | 21 | 0.050 |
Why?
| | Alanine | 1 | 2023 | 44 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2024 | 118 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 132 | 0.050 |
Why?
| | Recurrence | 2 | 2015 | 672 | 0.050 |
Why?
| | Antigens, CD | 1 | 2024 | 218 | 0.050 |
Why?
| | Oxidation-Reduction | 1 | 2023 | 326 | 0.050 |
Why?
| | Glutathione | 1 | 2023 | 305 | 0.050 |
Why?
| | Ivermectin | 1 | 2022 | 11 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 256 | 0.050 |
Why?
| | Amphetamine | 1 | 2022 | 38 | 0.050 |
Why?
| | Half-Life | 1 | 2022 | 88 | 0.050 |
Why?
| | Antioxidants | 1 | 2023 | 256 | 0.050 |
Why?
| | Macrophages | 1 | 2024 | 379 | 0.050 |
Why?
| | Duodenoscopy | 1 | 2020 | 2 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 83 | 0.040 |
Why?
| | Ileum | 1 | 2020 | 88 | 0.040 |
Why?
| | Adenosylhomocysteinase | 1 | 2020 | 9 | 0.040 |
Why?
| | Alcohol Dehydrogenase | 1 | 2020 | 38 | 0.040 |
Why?
| | Aldehyde Dehydrogenase | 1 | 2020 | 25 | 0.040 |
Why?
| | Colonoscopy | 1 | 2020 | 108 | 0.040 |
Why?
| | Epithelial Cells | 1 | 2021 | 215 | 0.040 |
Why?
| | Blastomyces | 1 | 2019 | 17 | 0.040 |
Why?
| | Oxidative Stress | 1 | 2023 | 807 | 0.040 |
Why?
| | Young Adult | 2 | 2020 | 4329 | 0.040 |
Why?
| | Drug Overdose | 1 | 2020 | 163 | 0.040 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2018 | 57 | 0.040 |
Why?
| | Dexamethasone | 1 | 2020 | 438 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2020 | 1026 | 0.030 |
Why?
| | Cell Movement | 1 | 2018 | 268 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2018 | 378 | 0.030 |
Why?
| | Adolescent | 2 | 2020 | 6739 | 0.030 |
Why?
| | Antifungal Agents | 1 | 2019 | 347 | 0.030 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 9 | 0.030 |
Why?
| | Ultrasonography, Doppler | 1 | 2015 | 42 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2015 | 68 | 0.030 |
Why?
| | Image Enhancement | 1 | 2015 | 52 | 0.030 |
Why?
| | Pancreas | 1 | 2015 | 71 | 0.030 |
Why?
| | Organometallic Compounds | 1 | 2015 | 43 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2018 | 772 | 0.030 |
Why?
| | Eye Infections, Bacterial | 1 | 2015 | 29 | 0.030 |
Why?
| | Disease Progression | 1 | 2018 | 871 | 0.030 |
Why?
| | Postoperative Care | 1 | 2015 | 104 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 2481 | 0.030 |
Why?
| | Models, Biological | 1 | 2018 | 735 | 0.030 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 1884 | 0.030 |
Why?
| | Blepharoplasty | 1 | 2014 | 9 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2018 | 1470 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 891 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2018 | 1478 | 0.030 |
Why?
| | Signal Transduction | 1 | 2018 | 1671 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2014 | 2867 | 0.020 |
Why?
| | Infant | 1 | 2014 | 3733 | 0.010 |
Why?
|
|
Allard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|